Bostwick Laboratories

Ma’lumki, O‘zbekiston demografik o‘sish ko‘rsatkichlari nisbatan yuqori bo‘lgan mamlakatlar toifasiga kiradi. Respublika aholisi sonining yillik o‘sishi 2 foizni, ya‘ni o‘rtacha 800 ming nafargacha kishini tashkil etmoqda118. Albatta bunday faol demografik o‘sish aholining yashash shart-sharoitlarini yaxshilash maqsadida ko‘plab ijtimoiy-iqtisosodiy chora-tadbirlarni o‘z vaqtida amalga oshirish bilan birgalikda mamlakatimizda uy-joylar qurilishini kengaytirish, shuningdek, aholi uchun qulay shartlarda yangi ipoteka kreditlarini ajratish imkoniyatlarini yaratishni taqozo etadi.

Introduction:This study assesses the accessibility and nature of parental leave policies during orthopaedic surgery residency training after implementation of the Accreditation Council for Graduate Medical Education (GME) mandate for 6 weeks of paid parental leave effective July of 2022.Materials and Methods:An audit of orthopaedic surgery residency and affiliated GME websites was conducted to assess the accessibility of parental leave policies during the 2023-2024 academic year. Details on length of leave and nature of renumeration during the leave were recorded. Bivariate analyses were conducted to determine residency program characteristics associated with the accessibility of a parental leave policy. Results were compared with a previous analysis during the 2017-2018 academic year.Results:A total of 200 residency programs were evaluated, and 152 had parental leave policies (76.0%). Compared with 2017 to 2018, a similar percentage of parental leave policies were accessible on residency program websites (3.0% vs. 2.0%, P = 0.777) but fewer were accessible on GME websites (55.5% vs. 80.7%, P < 0.001). More contemporary policies were obtained from program coordinators (18.5% vs. 7.2%, P = 0.003), and more were not available (24.0% vs. 9.0%, P < 0.001). Most policies offered renumeration (86.7%) and leave for 6 weeks in length (75.0%). A higher prevalence of parental leave policy accessibility was found among orthopaedic residency programs with university affiliation (P < 0.001), more faculty members (P = 0.008) and residents (P = 0.017), a higher percentage of female faculty (P = 0.008), affiliation with a top 50 ranked National Institutes of Health–funded orthopaedic surgery department, and accreditation achieved before 2017 to 2018 (P = 0.004).Discussion:Most orthopaedic surgery residency programs do not have accessible parental leave policies on their websites. The new Accreditation Council for GME mandate will require orthopaedic residency programs to provide residents with 6 weeks of paid parental leave during residency training. Accessible policies may be useful to applicants interested in child rearing during orthopaedic residency training.

The International Society of Urological Pathology (ISUP) hosts a reference image database supervised by experts with the purpose of establishing an international standard in prostate cancer grading. Here, we aimed to identify areas of grading difficulties and compare the results with those obtained from an artificial intelligence system trained in grading. In a series of 87 needle biopsies of cancers selected to include problematic cases, experts failed to reach a 2/3 consensus in 41.4% (36/87). Among consensus and non-consensus cases, the weighted kappa was 0.77 (range 0.68–0.84) and 0.50 (range 0.40–0.57), respectively. Among the non-consensus cases, four main causes of disagreement were identified: the distinction between Gleason score 3 + 3 with tangential cutting artifacts vs. Gleason score 3 + 4 with poorly formed or fused glands (13 cases), Gleason score 3 + 4 vs. 4 + 3 (7 cases), Gleason score 4 + 3 vs. 4 + 4 (8 cases) and the identification of a small component of Gleason pattern 5 (6 cases). The AI system obtained a weighted kappa value of 0.53 among the non-consensus cases, placing it as the observer with the sixth best reproducibility out of a total of 24. AI may serve as a decision support and decrease inter-observer variability by its ability to make consistent decisions. The grading of these cancer patterns that best predicts outcome and guides treatment warrants further clinical and genetic studies. Results of such investigations should be used to improve calibration of AI systems.

186 Background: Ferumoxytol (Feraheme) is a ferromagnetic nanoparticle with lymphotrophic biokinetics, delivered to lymph nodes by normal macrophages. MRI suppresses normal lymph nodes containing Feraheme. Objective is to validate safety and efficacy in finding lymph node positivity in prostate cancer (PCa). Methods: Nonrandomized prospective evaluation of 178 consecutive PCa patients (pts) at high risk for lymph node spread enrolled 2/13-3/15. All received IV Feraheme. 177 received 6/mg/kg over 20 min. One pt received 3 mg/kg infusion. T2 MEDIC and T2* sequence imaging of abdomen and pelvis, given 24 hours later. Images reviewed by 2 board certified radiologists with same interpretations, blinded to clinical and histo-path info (pre-MRI TNM stage/PSA/Gleason). Nodes were deemed abnormal if they did not suppress after Feraheme infusion (group 1, 94 patients). Nodes were deemed suspicious if suppressed and met usual size criteria with high signal intensity on DWI and decreased ADC map values and morphologic features (group 2, 84 pts). 83 group 1 pts had CT biopsies (77 pelvis, 6 retroperitoneum);11 pts had open PLND. 382 lymph nodes sampled. 76 group 2 patients had CT biopsies (73 pelvis, 3 retroperitoneum); 9 pts had open PLND. 340 lymph nodes sampled. Rad-path correlation was performed. Nodes were stained; reviewed by a single pathologist with no knowledge of MRI findings. Histo-path results for each node were cataloged for later MRI comparison. Results: 90 group 1 pts (96%) proved metastatic PCa; 4 pts (4%) were normal. 68 group 1 pts (77%) had malignant lymph nodes not meeting usual imaging criteria. 39 group 2 pts (47%) showed metastatic PCa; 46 pts (53%) were normal. One group 2 pt had an allergic reaction with hives; infusion ceased at 3mg/kg; pt treated to full resolution with 50 mg IV Benadryl. Conclusions: Feraheme can evaluate lymphatic dissemination of metastatic disease in PCa patients, with a lower limit of resolution of focal lymph node metastases of 2-3 mm. Better resolution gives implications for therapeutic radiation planning of newly diagnosed or recurrent/metastatic PCa. Toxicity was very acceptable at 6mg/kg. Feraheme may play a significant role as a lymphatic contrast agent in the early dissemination of lymphatic metastatic disease.

Objective. After filtration through glomeruli, β2-microglobulin is reabsorbed in proximal tubules. Increased urinary β2-microglobulin indicates proximal tubule injury and measurement of β2-microglobulin in urine is useful to determine the source of renal injury. Kidney injury molecule-1 (KIM-1) has been characterized as a selective proximal tubule injury marker. This study was designed to evaluate the correlation of urinary β2-microglobulin concentration and KIM-1 expression as evidence of proximal tubule injury. Methods. Between 2009 and 2012, 46 patients with urine β2-microglobulin (RenalVysion) had follow-up kidney biopsy. Diagnoses included glomerular and tubule-interstitial disease. Immunohistochemical staining for KIM-1 was performed and the intensity was graded from 0 to 3+. Linear regression analysis was applied to correlate the values of urinary β2-microglobulin and KIM-1 staining scores. P < 0.05 was considered statistically significant. Results. Thirty patients had elevated urinary β2-microglobulin. KIM-1 staining was positive in 35 kidney biopsies. There was a significant correlation between urinary β2-microglobulin and KIM-1 staining (P < 0.05). Sensitivity was 86.6%, specificity was 43.7%, positive predictive value was 74.2%, and negative predictive value was 63.6%. Conclusion. Increased urinary β2-microglobulin is significantly correlated with KIM-1 staining in injured proximal tubules. Measurement of urine β2-microglobulin is a sensitive assay for proximal tubule injury.

Background: Following the lead of lumpectomy for breast cancer, focal therapy for prostate cancer was introduced in order to limit morbidity while providing good cancer control. Focal therapy is now an established trend in prostate cancer management, but long-term data have not been available. This report presents results on 70 patients treated with focal cryoablation, followed for an average of 10 years. Methods: Between May 7, 1996, and December 28, 2005, seventy patients were treated with focal cryoablation. All patients were pre-staged using an additional prostate biopsy—either transrectal ultrasound (TRUS) biopsy or transperineal three-dimensional prostate mapping biopsy (3D-PMB). All patients were treated with focal cryoablation of the known tumor(s). Biochemical disease-free status was determined by the Phoenix criteria. Results: Disease-specific survival was 66/66 (100%). Overall biochemical disease-free survival (BDFS) was 62/70 (89%). BDFS results stratified according to the D'Amico criteria were: 8/9 (89%) high risk; 28/32 (88%) medium risk; and 26/29 (90%) low risk. There was no statistically significant difference between the risk levels. Of those patients staged by TRUS biopsy, 8 of 24 patients had a documented local recurrence (33%). Of those staged by (3D-PMB), 2 of 46 (4%) patients had a local recurrence. Nine out of ten retreated local recurrences (90%) remain BDF. Continence after the first treatment was 100% (no pads). Potency after the first treatment was 94%, including retreatments it was 74%. Conclusions: The long-term cancer control results of focal cryoablation appear superior in medium- and high-risk patients to radical whole gland treatments. Focal therapy is associated with extremely low morbidity. If confirmed and applied widely, focal cryoablation could result in a substantial decrease in prostate cancer related mortality while offering a better post treatment quality of life.

Acute rejection (AR) includes T-cell-mediated and antibody-mediated rejection. The inflammatory infiltrate comprised not only T cells but also varying amounts of B cells (CD20(+)) and plasma cells (CD138(+)). The latter are associated with poor clinical outcomes, but their functional status is not clear. The phosphorylation of the S6 ribosomal protein (p-S6RP) is present in cells that are metabolically active, thus identifying functionally active antibody-secreting plasma cells. This study was designed to evaluate the clinical significance of functionally active p-S6RP plasma cells in AR in renal allografts. Renal allografts with biopsy evidence of AR during 2006-2009 were included. Immunohistochemistry staining for CD20, CD138, and p-S6RP was performed on paraffin-embedded slides and scaled as 0-6. The response to antirejection treatment was assessed by the serum creatinine ratio (CrR) at rejection episode (time 0) and following treatment (4 and 12 weeks). Patients with lower scores (0-2) were compared with a higher scored group (3-6). The T-test was conducted using statistical significance of p<0.05. A total of 28 patients (40.7 ± 14.3 year; M:F=15:13) were diagnosed with acute T-cell-mediated rejection (I and II). The p-S6RP staining in the high-score group had a significantly higher CrR (p<0.05) than the low-score group at the time of biopsy, 4 and 12 weeks following treatment. There was no significant difference in the CrR between groups for CD20 or CD138 staining. Functional antibody-secreting p-S6RP plasma cells are actively participating in AR and associated with poor response to treatment in renal allografts.

In recent years, advances in our understanding of the molecular biology of prostate cancer have spawned optimism that new biomarkers will allow greater sensitivity and specificity in diagnosis as well as more accurate prediction of outcome after treatment for the individual patient. For at-risk patients with negative biopsy, multiple new markers are available, including mitochondrial DNA deletion testing (tissue), PCA3 (urine), and sarcosine (tissue or blood). For patients with diagnostically challenging prostate biopsies, multiple stain combinations (multiplex immunohistochemistry) such as quadruple staining with racemase, high-molecular-weight cytokeratin, p63, and c-myc are commonly used to confirm the diagnosis of prostate cancer; the recent addition of c-myc to create a quadruple stain provides additional diagnostic support for cancer, recognizing that there may be heterogeneity or complete lack of staining for some of the other markers. These stain combinations must, of necessity, be used together on 1 slide owing to common loss of the focus of concern on deeper sections. TMPRSS2:ERG is a useful diagnostic adjunct for select cases, with the recent introduction of antibody staining. Prostate-specific antigen, prostatic acid phosphatase, and prostate-specific membrane antigen are useful for confirming prostatic origin of cancers, as well as for predicting outcomes for select patient group. Other biomarkers are being actively investigated as companion diagnostics to predict response to treatment. This report describes the current state of immunohistochemical stains for the diagnosis of prostatic intraepithelial neoplasia, atypical small acinar proliferation, and prostate cancer.

Surgical pathology provides a window of opportunity to better understand a man’s unique prostate cancer, as tumors tend to be molecularly heterogeneous. Although hindsight is 20/20 vision, whole-mount pathological analysis provides the gold standard to compare the performance characteristics of prostate imaging modalities, accuracy of biopsy techniques, utility of preclinical blood/urine tests, and predictive algorithms that may be employed for patient selection. Whole-mount pathology allows characterization of the individual tumor(s) in terms of histological Gleason grade or aggressiveness and tumor volume. It also allows designation of three-dimensional spatial locations, in particular regarding proximity or involvement of the tumor to important structures such as the neurovascular bundles, prostatic capsule, urethra, and the seminal vesicles. The first step is to understand the disease process itself—where the cancers typically originate, how they disseminate, and whether the process involves a “field change” responsible for cancer multifocality.In this chapter, we aim to characterize prostate cancer in terms of number, location, invasiveness, and laterality based upon what is known in the literature. Once the histology of the oncologic process is appreciated, we can then use this information to better select candidates and predict those men who are likely to benefit from an organ-preserving treatment approach. Additional research is required to better understand the biology of each of the tumor foci within the prostate and to utilize this information to select patients for active surveillance, parenchyma-preserving approaches (focal therapy), or conventional whole-gland radical therapy.

INTRODUCTIONIIn 1972 Howie asked whether diagnosis was the Achilles heel of general practice. 1ccurate diagnosis was then, and remains, the fundamental concept of all medical practice.Are we any good at it now? HOW ARE WE DOING?This issue of the BJGP contains several papers on diagnosis and decision-making which shed light on this important area of practice.The results reported by Meechan et al give food for thought. 2 The researchers analysed national referrals for suspected cancer under the '2-Week Wait' rule (2WW) during 2009.Out of 865 494 referrals, 11% had cancer.Of all cancers being newly treated in that year, 43% were referred under the 2WW.So far -not bad.However, they also demonstrate wide disparity in practice, with clear evidence that some practices are good at diagnosing cancer while some are poor.This quality difference does not correlate with deprivation, region, practice size, or referral rates (which themselves vary threefold between practices 3 ).High-quality practices have high 'conversion rates': of those referred under the 2WW rule maybe 14% are diagnosed with cancer.However, the same practices also have high 'detection rates': of all cancers diagnosed in the practice, maybe 40% to 50% have been suspected and referred under the 2WW rule.In poorly performing practices the figures may be 4% and 17% respectively.The scatter diagram in Figure 1 of the Meechan et al paper is a powerful argument against complacency.If all practices were roughly the same the scatter diagram would look like a large spherical globular cluster with the spread explained by random variation.But that is not what the data show.In the practices in the top right of the main grouping, 20% to 30% of all patients referred under 2WW were diagnosed with cancer.Those same practices were detecting 60% to 70% of all cancers via 2WW referrals.In practices in the bottom left of the Meechan et al paper, maybe only 5% of those referred under the 2WW had cancer, yet only 10% of all cancers were detected via 2WW rule referrals.If this was random variation it would not explain the correlation between conversion rates and detection rates.